CLOSE

Benchmark Investments

Nippon India Nifty Pharma ETF

very highequityindex
23.15 -0.12(-0.50%) NAV as on 27 Mar 2026
-1.7 % 1 M
6.59 % 1 Y
24.38 % 3 Y

Growth Chart of the Scheme vis a vis benchmark

  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 3Y
  • 5Y
  • 10Y

SCHEME DETAILS

Expenses Ratio :

0.21

As on 28 Feb, 2026
Age :

4 yrs 8 m

Since 06 07 ,2021
Exit Load :

%

AUM :

1,058.55 Crs

Portfolio Price To Book Value :

6.11

Investing Style :

Large Growth

Min. Investment :

SIP NA & Lumpsum 1000

Category :

etfs

Fund Manager :

Jitendra Tolani

Launch Date :

06-Jul-21

Scheme Benchmark :

NA

FUND OBJECTIVE

The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.

RISKOMETER Level of Risk in the Scheme

Investors understand that their principal will be at very high risk

LATEST ASSET & PORTFOLIO ALLOCATION

as on Feb 28 ,2026
Others 0.08 %
Equity 99.92 %

TOP HOLDINGS

Sun Pharmaceutical Industries...21.93 %
Divi's Laboratories Ltd.9.71 %
Dr. Reddy's Laboratories Ltd.9.35 %
Cipla Ltd.9.04 %
Lupin Ltd.6.65 %
See All Holding

ALLOCATION BY MARKET CAP

ALLOCATION BY SECTOR

Pharmaceuticals & Drugs99.92
See All Sectors

5-YEARS HISTORY

Financial Year2021-20222022-20232023-20242024-20252025-2026
NAV in Rs (as on 27-Mar-2026)13.6512.1619.3221.5823.15
Net Assets(Rs Crores) (as on 27-Mar-2026) 87.63 197.85 643.07 856.43 1058.55
Scheme Returns(%)(Absolute)-5.25-10.9258.2110.489.18
B'mark Returns(%)(Absolute)NANANANANA
Category Rank109/111150/16029/20139/23865/320

Quarterly Performance - Last 5 Years (Absolute Ret. In %)

Financial Year Q1 Q2 Q3 Q4
2025-20264.34-2.375.88NA
2024-20253.8418.320.53-9.56
2023-202414.5312.509.1113.01
2022-2023-10.467.10-2.90-4.37
2021-2022NANA-1.68-4.27

PERFORMANCE COMPARISON WITH SIMILAR SCHEMES

Nippon India Nifty Pharma ETFVery HighEquity23.15-0.12(-0.50%)NAV As on 29 Mar, 202606-Jul-2021Inception Date1,058.55AUM In Cr.6.59%1Y24.38%3YNA%5Y10.55%Since Inception
DSP Nifty 50 Equal Weight ETFVery HighEquity313.02-5.22(-1.64%)NAV As on 29 Mar, 202608-Nov-2021Inception Date1,165.43AUM In Cr.3.41%1Y16.92%3YNA%5Y10.45%Since Inception
ICICI Pru Nifty 50 ETFVery HighEquity256.86-5.48(-2.09%)NAV As on 29 Mar, 202620-Mar-2013Inception Date37,938.73AUM In Cr.-2.22%1Y11.58%3Y10.71%5Y12.48%Since Inception
Aditya Birla SL Nifty 50 ETFVery HighEquity26.57-0.57(-2.09%)NAV As on 29 Mar, 202621-Jul-2011Inception Date3,263.94AUM In Cr.-2.19%1Y11.58%3Y10.71%5Y11.26%Since Inception
Nippon India ETF Nifty 50 BeESVery HighEquity258.18-5.51(-2.09%)NAV As on 29 Mar, 202628-Dec-2001Inception Date57,632.90AUM In Cr.-2.23%1Y11.57%3Y10.70%5Y14.86%Since Inception
UTI Nifty 50 ETFVery HighEquity251.27-5.36(-2.09%)NAV As on 29 Mar, 202601-Sep-2015Inception Date69,057.50AUM In Cr.-2.21%1Y11.57%3Y10.69%5Y11.97%Since Inception

BENCHMARK INVESTMENTS

Benchmark Investments, 6 Sector II Shanti Niketan, Govindpura Bhopal, Bhopal-462023, India. +91-755-4938282/+91-9826310337 hello@benchmarkinvestments.in.
Downloads
Quick Links
Useful Links

Mutual fund and other investments are always subject to market risks. Please read all, Scheme Information Documents (SID), Key Information Memorandum (KIM), Addendums(if any) issued there to from time to time and any other related documents or information carefully before investing. Past performance is not indicative or assurance of future performance or returns. Please consider your specific investment requirements before choosing a fund.

For any grievances, investors can contact at: hello@benchmarkinvestments.in,  Tel: +91-755-4938282 / +91-9826310337.
©  Copyrights 2022 , Benchmark Investments | All Rights Reserved |  Designed, Developed & Content Powered by Accord Fintech Pvt Ltd